(a) OAC 340:100-5-26.1 applies to service recipients receiving:
(b) A psychotropic medication is a pharmacological drug used to treat a mental disorder, or any drug prescribed to stabilize or improve mood, mental status, or behavior.
(c) Medication is not used as punishment, for the convenience of staff, as a substitute for a program, or in quantities that interfere with a service recipient's participation in programming.
(d) The service recipient's Personal Support Team (Team) obtains from the prescribing physician a description of data to be collected to evaluate the effectiveness of the psychotropic medication.
(e) Developmental Disabilities Services Division (DDSD) staff and contract providers are not authorized to administer psychotropic medications on a p.r.n. basis, except under very limited circumstances as approved by the respective DDSD area medical director or designee using Form 06HM065E, Request for Approval of Psychotropic p.r.n. Medications.
(f) Psychotropic medication is monitored in accordance with OAC 340:100-5-26.
(g) Monitoring for side effects such as tardive dyskinesia is in accordance with OAC 340:100-5-29.
(h) The Team implements positive support strategies according to OAC 340:100-5-57.
(i) The Team's review of the use of psychotropic medication via Form 06HM067E, Semi-Annual Psychotropic Medication Review, includes discussion, prior to implementation and at least twice a year thereafter, of:
-
(1) possible less restrictive alternatives;
-
(2) the role that health and environmental factors may contribute to the challenging behavior;
-
(3) diagnosis;
-
(4) functional assessment;
-
(5) expected length of treatment;
-
(6) symptoms;
-
(7) expected benefits of the medication;
-
(8) possible risks and adverse effects of the medication;
-
(9) data collection methods;
-
(10) ongoing communication with the prescribing physician or psychiatrist; and
-
(11) past interventions and outcomes.
(j) If psychotropic medication is ordered on an emergency basis, the Team meets with appropriate service providers to review considerations per OAC 340:100-5-26.1(i) as soon as possible, but within five working days.
(k) Notes of the Team's discussion from the meetings required per OAC 340:100‑5‑26.1(i) and (j) are provided to the prescribing physician for review and consideration of optimal effective dosage. Optimal effective dosage is the least amount of medication required to improve or stabilize the problem.
(l) Psychotropic medication is considered to be in use only for behavioral control if prescribed without a confirmed medical or psychiatric diagnosis appropriate for the medication.
(2) Ineffective medication. When the service recipient and service recipient's Team determine the medication is ineffective in eliminating or substantially reducing targeted behaviors, documentation and review are required as described in (A) through (C).
-
(A) The Team must provide input and meet as needed, but at least quarterly, with the prescribing psychiatrist or physician to:
-
(i) provide pertinent information about the service recipient's status; and
-
(ii) review the need for continuing, changing, or discontinuing the medication.
-
(B) Documentation of the input and physician's response must be submitted to the positive support field specialist for review by SBRC.
-
(C) The Team must annually submit a protective intervention plan, that includes a physician-approved psychotropic reduction or adjustment plan, to HRC for review and SBRC for approval.